Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Deals

Sanyou Biopharmaceuticals and Huadong Medicine Expand Partnership on Macromolecule Therapeutics

Fineline Cube Jun 28, 2023

China-based Sanyou Biopharmaceuticals Co., Ltd has announced a licensing deal with compatriot firm Huadong Medicine...

Company Drug

Daewoong Pharmaceutical Files NDA in China for Potassium-Competitive Acid Blocker Fexuclu

Fineline Cube Jun 28, 2023

South Korea-based Daewoong Pharmaceutical (KRX: 069620) has revealed that a new drug application (NDA) has...

Company Drug

Insilico Medicine’s AI-Discovered Drug INS018_055 Reaches Phase II Clinical Trial Milestone

Fineline Cube Jun 28, 2023

China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has announced that its lead pipeline candidate,...

Company Deals

Biomm Secures Late-Stage Biosimilar Candidate BAT2206 from Bio-Thera Solutions

Fineline Cube Jun 27, 2023

Brazil-based biotechnology company Biomm (BVMF: BIOM3) has announced that it has in-licensed the late-stage biosimilar...

Policy / Regulatory

CDE Issues Guidelines for New Drug Benefit-Risk Assessment in Market Approval Filings

Fineline Cube Jun 27, 2023

The Center for Drug Evaluation (CDE) has released a notice outlining the guidelines for “New...

Legal / IP Policy / Regulatory

CNIPA Launches Pilot for Priority Patent Review for Macau Applicants in Mainland China

Fineline Cube Jun 27, 2023

The China National Intellectual Property Administration (CNIPA) has announced the commencement of a pilot program...

Company Drug

AstraZeneca’s Dapagliflozin and Metformin Combo Approved by China’s NMPA for Type 2 Diabetes

Fineline Cube Jun 27, 2023

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received market approval...

Company Deals

Lion TCR Secures RMB 300 Million in Series B2 Financing to Advance Clinical Studies and Facility Construction

Fineline Cube Jun 27, 2023

Singapore-based clinical-stage biotechnology company Lion TCR has announced the successful completion of its Series B2...

Company Drug

LianBio’s Mavacamten Receives Priority Review Status from China’s CDE for oHCM Treatment

Fineline Cube Jun 27, 2023

The Center for Drug Evaluation (CDE) has indicated on its website that China-based biotech firm...

Company Drug

CSPC Pharmaceutical Group Gets NMPA Approval for JMT203 Cancer Cachexia Clinical Study

Fineline Cube Jun 27, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Policy / Regulatory

NMPA Releases 69th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Jun 27, 2023

The National Medical Products Administration (NMPA) has released the 69th batch of reference drugs for...

Company Deals

BDgene Technology Secures Over RMB 200 Million in Series B Financing Led by Lapam Capital

Fineline Cube Jun 27, 2023

Gene therapy specialist Shanghai BDgene Technology Co., Ltd has successfully raised over RMB 200 million...

Company Deals

WuXi Biologics Partners with Pharmadule Morimatsu AB for CRDMO Expansion in Singapore

Fineline Cube Jun 27, 2023

China-based WuXi Biologics (HKG: 2269) has announced a strategic partnership with Sweden-headquartered Pharmadule Morimatsu AB...

Company Drug

CStone Pharmaceuticals’ Gavreto Approved for First-Line RET Fusion-Positive NSCLC Treatment in China

Fineline Cube Jun 27, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) of...

Company Drug

CSPC Pharmaceutical’s Biosimilar Omalizumab Accepted for Review by China’s NMPA

Fineline Cube Jun 27, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that the National Medical Products Administration...

Company Drug

Henlius Biotech’s HLX13 Biosimilar Gets NMPA Approval for Liver Cancer Clinical Trial

Fineline Cube Jun 27, 2023

Shanghai Henlius Biotech, Inc (HKG: 2696) has announced receiving clinical trial approval from the National...

Company Drug

Chia Tai Tianqing Launches First Batch of F-627 for Neutropenia Treatment in China

Fineline Cube Jun 27, 2023

China-based Chia Tai Tianqing has announced the first batch prescriptions in China for its efbemalenograstim...

Company Drug

Jiangsu Kanion Pharmaceutical Gets FDA Approval for KYS202002A Clinical Study in Multiple Myeloma

Fineline Cube Jun 27, 2023

China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving the green light from...

Company Deals

Mega Lifesciences Secures Exclusive Rights for Bio-Thera’s Bevacizumab Biosimilar in Indonesia

Fineline Cube Jun 27, 2023

Thailand-based Mega Lifesciences (BKK: MEGA) has announced an in-licensing agreement with China-based Bio-Thera Solutions (SHA:...

Company Drug

Jiangsu Hengrui’s Dalpiciclib Approved for Initial Therapy in HR+, HER2- Breast Cancer

Fineline Cube Jun 27, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Posts pagination

1 … 510 511 512 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.